Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Results from the sub analysis of the AURORA trial

Elisa Agostinetto, MD, Institut Jules Bordet, Brussels, Belgium, details the sub-analysis of the AURORA trial (NCT02102165), a molecular screening initiative led by the breast international group (BIG). For patients with hormone receptor-positive, HER2-negative metastatic breast cancer, CDK4/6 inhibitors combined with endocrine therapy is the standard of care (SOC) in the first-line setting. The aim of the sub-analysis was to identify the clinical, pathological, and molecular trends linked with prognosis in these patients who do not benefit from the SOC. Patients with a primary endocrine resistance had a significantly shorter progression-free survival (PFS) compared to patients who are endocrine sensitive/naïve to therapy. Certain mutations were also linked with a shorter PFS, such as in TP53 and ESR1, which can aid in the formation of a clinical trial to test alternative treatment methods. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.